CIK 0001472012 · Non-accelerated filer
Immunome Inc.
Sign in to watch- Ticker
- IMNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770694340
- Phone
- 610-321-3700
- Business address
- 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $334,224
- in 1 filing, $334K under 10b5-1 plans
Net −$334,224. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 56 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-30 | Barchas Isaac Director | Sale 10b5-1 | −101,050 | $21.12 | $2.1M | 308,504 |
| 2026-06-25 | Lechleider Robert Chief Medical Officer | Option exercise 10b5-1 | +55,000 | $8.73 | $480K | 70,805 |
| 2026-06-25 | Lechleider Robert Chief Medical Officer | Sale 10b5-1 | −40,580 | $19.56 | $794K | 30,225 |
| 2026-06-25 | Lechleider Robert Chief Medical Officer | Sale 10b5-1 | −14,420 | $20.66 | $298K | 15,805 |
| 2026-06-25 | Lechleider Robert Chief Medical Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −55,000 | 345,000 | ||
| 2026-06-15 | Rosett Max Chief Financial Officer | Option exercise 10b5-1 | +60,000 | $1.05 | $63K | 114,037 |
| 2026-06-15 | Rosett Max Chief Financial Officer | Sale 10b5-1 | −60,000 | $18.23 | $1.1M | 54,037 |
| 2026-06-15 | Rosett Max Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −60,000 | 0 | ||
| 2026-06-10 | Boylan James P Director | Grant or award · Director Stock Option (right to buy) | +9,897 | 9,897 | ||
| 2026-06-10 | SWAIN SANDRA M Director | Grant or award · Director Stock Option (right to buy)` | +9,897 | 9,897 | ||
| 2026-06-10 | Barchas Isaac Director | Grant or award · Director Stock Option (right to buy) | +9,897 | 9,897 | ||
| 2026-06-10 | WAGENHEIM PHILIP Director | Grant or award · Director Stock Option (right to buy) | +9,897 | 9,897 | ||
| 2026-06-10 | SCHAFER CAROL Director | Grant or award · Director Stock Option (right to buy) | +9,897 | 9,897 | ||
| 2026-06-10 | BIENAIME JEAN JACQUES Director | Grant or award · Director Stock Option (right to buy) | +9,897 | 9,897 | ||
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Sale | −500 | $19.44 | $10K | 42,915 |
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Sale | −10,000 | $19.41 | $194K | 32,915 |
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Purchase | +6,000 | $19.48 | $117K | 38,915 |
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Purchase | +3,500 | $19.46 | $68K | 42,415 |
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Purchase | +1,000 | $19.27 | $19K | 43,415 |
| 2026-05-15 | BIENAIME JEAN JACQUES Director | Purchase | +5,000 | $20.70 | $104K | 43,415 |
Page 3 of 8 · 159 trades